LIXT Lixte Biotechnology Holdings Inc.

3.2
-0.09  -3%
Previous Close 3.29
Open 3.24
52 Week Low 3
52 Week High 7.86
Market Cap $43,322,429
Shares 13,538,259
Float 5,265,679
Enterprise Value $42,971,606
Volume 42,236
Av. Daily Volume 1,319,585
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
LB-100
Myelodysplastic Syndromes (MDS)
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
LB-100
Glioblastoma Multiforme
Phase 2
Phase 2
Phase 2 trial ongoing.

Latest News

    • More than 40 preclinical studies have found that Lixte's lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity

    EAST SETAUKET, NY, March 17, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual Benzinga Biotech Small Cap Conference being held March 24-25, 2021. Lixte Founder and Chief Executive Officer John S. Kovach, M.D., will present on Wednesday, March 24 at 10:55 a.m. ET in Track 1. Investors may register for the conference at the event website.

    During the corporate presentation and in one-on-one…

    • More than 40 preclinical studies have found that Lixte's lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity

    EAST SETAUKET, NY, March 17, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual Benzinga Biotech Small Cap Conference being held March 24-25, 2021. Lixte Founder and Chief Executive Officer John S. Kovach, M.D., will present on Wednesday, March 24 at 10:55 a.m. ET in Track 1. Investors may register for the conference at the event website.

    During the corporate presentation and in one-on-one investor meetings, Dr. Kovach will discuss Lixte's product pipeline of ongoing studies and planned trials of its lead clinical candidate LB-100, a unique first-in-class anti-cancer agent with no competitors known to Lixte currently in the clinic.

    Dr. Kovach commented, "More than 40 preclinical studies with leading medical centers indicated that LB-100 enhances standard therapies for many cancers. We now have a number of exciting clinical investigations underway for LB-100, including three clinical trials and one pharmacology study. Our initial cancer targets are myelodysplastic syndrome, soft tissue sarcomas, small cell lung cancer, and glioblastoma."

    About Lixte Biotechnology Holdings, Inc.

    Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. lixte.com

    Forward-Looking Statements

    This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.

    Lixte Contact:



    General Phone: (631) 830-7092

    Investor Phone: (888) 289-5533



    Primary Logo

    View Full Article Hide Full Article
    • LB-100 is Currently in Clinical Studies for Four Cancer Targets:
      • Phase 1b/2 for Myelodysplastic (MDS) Syndromes
      • Phase 1b/2 for Advanced Soft Tissue Sarcoma
      • Phase 0 (Pharmacodynamics) for Glioblastoma Multiforme
      • Phase 1b for Small Cell Lung Cancer
      • Pre-clinical for Angelman Syndrome

    EAST SETAUKET, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual 33rd Annual Roth Conference, being held March 15-17, 2021. Investors may register and consult the conference agenda at the event website.

    A webcast of Lixte's investor presentation by Founder and Chief Executive Officer…

    • LB-100 is Currently in Clinical Studies for Four Cancer Targets:
      • Phase 1b/2 for Myelodysplastic (MDS) Syndromes
      • Phase 1b/2 for Advanced Soft Tissue Sarcoma
      • Phase 0 (Pharmacodynamics) for Glioblastoma Multiforme
      • Phase 1b for Small Cell Lung Cancer
      • Pre-clinical for Angelman Syndrome

    EAST SETAUKET, NY, March 03, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will participate in the virtual 33rd Annual Roth Conference, being held March 15-17, 2021. Investors may register and consult the conference agenda at the event website.

    A webcast of Lixte's investor presentation by Founder and Chief Executive Officer John S. Kovach, M.D. will be available on demand at the event website and at Lixte's website under Investor Information: News & Events. A replay of the webcast will be available on the Company's website for 12 months following the conference.

    During the corporate presentation and in one-on-one and small group investor meetings, Dr. Kovach will discuss the Company's proprietary clinical stage compound LB-100, a first in-class protein phosphatase (PP2A) inhibitor that increases the anti-tumor activity of standard chemotherapy, radiotherapy, and immunotherapy without increasing toxicity. LB-100 is initially being evaluated in three clinical treatment studies (phase 1b/2 for Myelodysplastic Syndromes, Advanced Soft Tissue Sarcoma, and Small Cell Lung Cancer and in a phase 0 (human pharmacodynamic/pharmacokinetic study) in recurrent gliomas. LB-100 is also being tested for potential benefit in a rodent model of Angelman Syndrome, a severe neurodevelopmental disorder. There are no direct competitors of LB-100 known to Lixte in the clinic at present.

    Dr. Kovach commented, "LB-100 causes cancer cells, injured by chemo or radiotherapy, to continue to replicate before repairing their injuries, leading to more efficient cancer cell killing by many standard anti-cancer regimens. If the improvement of standard treatments for diverse cancers by LB-100 is documented in the clinic, our first-in-class compound will be a game-changing advance in cancer therapy worldwide."

    About Lixte Biotechnology Holdings, Inc.

    Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. lixte.com

    Forward-Looking Statements

    This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.

    Lixte Contact:



    General Phone: (631) 830-7092

    Investor Phone: (888) 289-5533



    Primary Logo

    View Full Article Hide Full Article
  1. WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, with certain institutional and accredited investors for $4.19 million of common stock. The Company issued a total of 1,133,102 shares of common stock, at a purchase price of $3.70 per share.

    WestPark Capital acted as Co-Placement Agent for the offering.

    The shares of common stock were offered by Lixte pursuant to a "shelf" registration statement on Form S-3 (File No. 333-252430) previously filed with the Securities and Exchange Commission…

    WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, with certain institutional and accredited investors for $4.19 million of common stock. The Company issued a total of 1,133,102 shares of common stock, at a purchase price of $3.70 per share.

    WestPark Capital acted as Co-Placement Agent for the offering.

    The shares of common stock were offered by Lixte pursuant to a "shelf" registration statement on Form S-3 (File No. 333-252430) previously filed with the Securities and Exchange Commission (the "SEC") on January 26, 2021, and declared effective by the SEC on February 5, 2021.

    A prospectus supplement and accompanying prospectus relating to the securities being offered have been filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC's website at http://www.sec.gov or from: WestPark Capital, Inc. – Attention: Jason Stern, 1900 Avenue of the Stars, 3rd Floor, Los Angeles, CA 90077 or by Email: or by telephone at (310) 203-2919.

    Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the Offering. This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

    About WestPark Capital, Inc.

    WestPark Capital is a full-service investment bank focused on emerging growth sectors such as healthcare, software, technology, biotechnology, financial services, manufacturing, consumer products, media and telecom industries, among other categories. WestPark Capital provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements, CMPOs, RDs, ATM, SIPOs and corporate finance advisory services. Additional information about WestPark Capital is available at www.wpcapital.com or at .

    About Lixte Biotechnology Holdings, Inc.

    Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. Their product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that they believe have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. Additional information about Lixte Biotechnology Holdings, Inc. is available at .

    View Full Article Hide Full Article
  2. JERSEY CITY, N.J., March 2, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment with certain institutional and accredited investors for $4.19 million of common stock. The Company issued a total of 1,133,102 shares of common stock, at a purchase price of $3.70 per share. 

    WallachBeth Capital, LLC acted as Co-Placement Agent for the offering.

    The gross proceeds to Lixte from this offering are expected to be approximately $4.19 million before deducting the placement agents' fees and other offering expenses payable by Lixte. The company intends to use the net proceeds from the offering for working capital and general expenses including further development of its lead clinical compound LB-100.

    The shares of common stock were offered by Lixte pursuant to a "shelf" registration statement on Form S-3 (File No. 333-252430) previously filed with the Securities and Exchange Commission (the "SEC") on January 26, 2021 and declared effective by the SEC on February 5, 2021.

    A prospectus supplement and accompanying prospectus relating to the securities being offered have been filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC's website at http://www.sec.gov or from: WestPark Capital, Inc. - Attention: Jason Stern, 1900 Avenue of the Stars, 3rd Floor, Los Angeles, CA 90077 or by Email: or by telephone at (310) 203-2919.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Lixte Biotechnology Holdings, Inc.

    Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, weakened by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is currently being tested in three clinical studies with others in planning. www.lixte.com

    About WallachBeth Capital LLC

    WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, creating value for both issuers and investors. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions. WallachBeth Capital is a leading provider of institutional execution services, offering clients a full spectrum of solutions to help them navigate increasingly complex markets. The firm's website is located at www.wallachbeth.com.

    Forward-Looking Statements

    This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/wallachbeth-capital-announces-completion-of-4-19-million-registered-direct-offering-for-lixte-biotechnology-holdings-inc-301238992.html

    SOURCE WallachBeth Capital LLC

    View Full Article Hide Full Article
  3. East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $4.19 million of common stock. The Company issued a total of 1,133,102 shares of common stock, at a purchase price of $3.70 per share.

    WestPark Capital, Inc. and WallachBeth Capital, LLC acted as co-placement agents for the offering.

    The gross proceeds to Lixte from this offering are expected to be approximately $4.19 million before deducting the placement agents' fees and other offering expenses payable by Lixte. The…

    East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $4.19 million of common stock. The Company issued a total of 1,133,102 shares of common stock, at a purchase price of $3.70 per share.

    WestPark Capital, Inc. and WallachBeth Capital, LLC acted as co-placement agents for the offering.

    The gross proceeds to Lixte from this offering are expected to be approximately $4.19 million before deducting the placement agents' fees and other offering expenses payable by Lixte. The company intends to use the net proceeds from the offering for working capital and general expenses including further development of its lead clinical compound LB-100.

    The shares of common stock were offered by Lixte pursuant to a "shelf" registration statement on Form S-3 (File No. 333-252430) previously filed with the Securities and Exchange Commission (the "SEC") on January 26, 2021 and declared effective by the SEC on February 5, 2021.

    A prospectus supplement and accompanying prospectus relating to the securities being offered have been filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC's website at http://www.sec.gov or from: WestPark Capital, Inc. - Attention: Jason Stern, 1900 Avenue of the Stars, 3rd Floor, Los Angeles, CA 90077 or by Email: or by telephone at (310) 203-2919.

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

    About Lixte Biotechnology Holdings, Inc.

    Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the "on" switches because the "off" switches, especially the master "off" switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, weakened by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is currently being tested in three clinical studies with others in planning. www.lixte.com

    Forward-Looking Statements

    This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.

    Lixte Contact:



    General Phone: (631) 830-7092

    Investor Phone: (888) 289-5533



    Primary Logo

    View Full Article Hide Full Article
View All Lixte Biotechnology Holdings Inc. News